The World Health Organization (WHO) and the International Consensus Classification (ICC) have both granted recognition to primary cold agglutinin disease (CAD) as a new diagnostic entity, based on case study findings from Italy published in the journal Histopathology. Primary CAD is an autoimmune hemolytic anemia that is associated with monoclonal cold agglutinin autoantibodies that cause…
Pharmacokinetic (PK) and pharmacodynamic (PD) data for sutimlimab (Enjaymo®) support the approved dosing regimen in patients with cold agglutinin disease (CAD), without the need for further dose adjustments in specific populations, according to a study published in the Journal of Pharmacology and Experimental Therapeutics. The approved dosing (6.5 g in patients weighing less than 75 kg,…
Researchers wrote about a symptom and impact questionnaire they developed for patients with cold agglutinin disease (CAD) in the European Journal of Hematology. CAD accounts for around one-quarter of all cases of autoimmune hemolytic anemia. Manifestations of the disease are more apparent in cold environments, and patients who experience symptoms of CAD typically complain of…
Patients with immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) can develop IgM-related disorders, such as cold agglutinin disease (CAD), peripheral neuropathy, and/or cryoglobulinemia, according to findings from a study published in Haematologica. Individuals with IgG or IgA MGUS usually develop multiple myeloma or other plasma cell neoplasms, whereas those with IgM MGUS typically…
Researchers presented the case report of a patient who experienced signs of cold agglutinin disease (CAD) during cardiopulmonary bypass. The report appears in the Annals of Cardiac Anaesthesia. A 45-year-old woman was scheduled for balloon mitral valvotomy. Intraoperatively, the patient’s posterior mitral leaflet ruptured, causing severe mitral regurgitation. Her surgeons decided she should undergo emergency…
Peritransfusional C1-inhibitor (C1-INH) demonstrated its ability to temporarily reduce complement activation but failed to suppress hemolytic activity in severe transfusion-dependent complement-mediated autoimmune hemolytic anemia (CM-AIHA) such as cold agglutinin disease (CAD), according to a study published in Blood Advances. For this prospective, single-center, phase 2 open-label trial, the authors recruited 10 patients with established CM-AIHA…
A multinational, multicenter, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS) is now recruiting. Patients with CAD or CAS aged at least 18 years old are considered eligible for the study, regardless of the type of therapy they are receiving. The study…
There might be a significant association between high grades of direct antiglobulin test (DAT) results and the severity of anemia, hemolysis, and jaundice in patients with autoimmune hemolytic anemia (AIHA), both warm and cold types such as cold agglutinin disease (CAD), according to a study published in the Asian Journal of Medical Sciences. The researchers…
Researchers presented the case report of a patient who was diagnosed with autoimmune hemolytic anemia and sarcoidosis in Authorea. The healthcare providers in the case worked to determine whether the patient’s autoimmune hemolytic anemia could have been driven by cold agglutinins, such as in the case of cold agglutinin disease (CAD). Sarcoidosis is often accompanied…
Clinicians presented the case of a 71-year-old woman who was diagnosed with refractory hemolytic anemia in The New England Journal of Medicine. The patient had a 7-month history of fatigue and dyspnea, which worsened on exertion. She was on breast cancer follow-up and had diffuse cutaneous systemic sclerosis. Blood investigations revealed anemia, and a peripheral…
Please login or register first to view this content.
